Nexus Precision Health, a precision medicine technology company, has acquired Leal Health, an AI-powered patient decision-support platform.

The acquisition creates an integrated platform designed to match patients with cancer, rare genetic diseases, and mental health conditions to the right therapy, clinical trial, or expanded access pathway—at scale.

Leal Health brings a patented GEN- AI engine that generates personalized treatment plans, along with a live ecosystem of 40,000+ clinicians, 90+ biopharma partners, and engagements with two of the five largest U.S. health insurers.

Leal Health’s capabilities enable advanced GEN- AI technologies to quickly and inexpensively amass real-world data, generate a treatment plan, educate both physicians and patients, and create a painless pathway to ordering the right test—helping patients access better treatments sooner, empowering doctors with actionable intelligence, and reducing waste across healthcare systems.

“This is a category-building moment that makes precision medicine executable at scale,” said Ascher Shmulewitz, Executive Chairman of Nexus Precision Health. “Together, we can turn precision medicine from a promise into a repeatable system.”

“I founded Leal Health because I believe every patient deserves an unbiased view of all their options,” remarked Tzvia Bader, CEO of Leal Health, who joins the Nexus executive leadership team. “By joining Nexus, we can expand the mission into rare genetic diseases and mental health.”

Terms of the transaction were not disclosed.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.